Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Shingrix Reactogenicity on QoL in Adults ≥ 50 Years
NCT02979639Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2017
- Primary completion
- Apr 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of herpes zoster vaccine (recombinant, adjuvanted) in herpes zoster (HZ), sponsored by GSK. Started Jan 2017; status: completed.
02
Drugs
herpes zoster vaccine (recombinant, adjuvanted)
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT02979639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02979639.